Skip to main content
Log in

Where have all the antibiotic patents gone?

  • Patents
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Patent and regulatory hurdles combined with low returns on investment are stifling antibiotic R&D in the pharmaceutical industry.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Antibacterial sales forecasts from 2005 to 2015, and key patent expirations.

References

  1. Bad bugs, no drugs: as antibiotic R&D stagnates... a public health crisis brews (Infectious Diseases Society of America, Alexandria, Virginia, 2004).

  2. Utility Examination Guidelines, 66 Fed. Reg. 1092 http://www.uspto.gov/web/officer/com/sol/notices/utilexmguide.pdf (2001).

  3. Tufts Center for the Study of Drug Development pegs cost of a new prescription medicine at $802 million. http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=6 (2001).

  4. Fermini, B. & Fossa, A.A. Nat. Rev. Drug Discov. 2, 439–447 (2003).

    Article  CAS  Google Scholar 

  5. Harris, G. Approval of antibiotic worried safety officials. New York Times (19 July 2006).

    Google Scholar 

  6. FDA rejects Replidyne drug application. Denver Business Journal (23 October 2006).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Katz, M., Mueller, L., Polyakov, M. et al. Where have all the antibiotic patents gone?. Nat Biotechnol 24, 1529–1531 (2006). https://doi.org/10.1038/nbt1206-1529

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1206-1529

  • Springer Nature America, Inc.

This article is cited by

Navigation